We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Immunovant Inc | NASDAQ:IMVT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.23 | -4.51% | 26.06 | 25.52 | 27.17 | 27.19 | 25.865 | 27.09 | 1,469,197 | 00:00:00 |
From Jun 2023 to Jun 2024
By Sabela Ojea
Immunovant said it received positive data from its ongoing 24-week Phase 2 clinical trial for its batoclimab treatment for Graves' disease.
The clinical-stage immunology company on Wednesday said the trial results in patients with Graves' disease meaningfully exceeded 50% response rates.
Batoclimab was generally well tolerated with no new safety signals observed in the initial data set.
Graves' disease is an immune system disorder.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
December 20, 2023 17:25 ET (22:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Immunovant Chart |
1 Month Immunovant Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
